Supply Chain Council of European Union | Scceu.org
Procurement

Stocks end little change after partial trade deal

U.S. stocks eked out gains Friday to close at records, as investors weighed a limited trade agreement between Washington and Beijing. 

Stocks initially jumped on the news that the world’s two largest economies had reached a “Phase 1” deal that eliminated new tariffs on Chinese goods that had been scheduled to start this weekend.

But the market gave up early gains to end Friday’s trading session little changed as investors parsed details of the accord. Technology stocks, which have been caught in the crosshairs of the trade battle, bounced higher on signs of easing tensions between the countries. But shares declined in other trade-sensitive corners of the market, including material and industrial stocks. 

One reason for the muted reaction among investors Friday, according to analysts, was that parts of the deal fell short of investors’ hopes. 

“Investors were likely looking for a larger rollback of the tariffs in place, but the important takeaway here is that things are continuing to de-escalate,” Charlie Ripley, senior investment strategist at Allianz Investment Management, said in a note.

Digital world map with stock market charts indicating gains.

On Friday, the Dow Jones industrial average ticked up 3 points, or less than 0.1%, to close at 28,135.38. The Standard & Poor’s 500 rose less than 0.1% to end at 3,168.80, a new record. The Nasdaq Composite climbed 0.2% to finish at 8,734.88, also a new all-time high. 

For the week, the blue-chip average gained 0.4%, and the broad S&P 500 and technology-heavy Nasdaq rose 0.7% and 0.9%, respectively.

Related posts

COVID-19 Impact and Recovery Analysis | Electroplating Market Procurement Intelligence Report Forecasts Spend Growth of Over USD 2 Billion – Northeast Mississippi Daily Journal

scceu

Internal Affairs addresses ‘significant fiscal risk’ to Common Capabilities ICT procurement

scceu

With Booster Doses, Shots for Children, Will Govt Take a More Pragmatic View on Vaccine Procurement?

scceu